Sequenom Selects PDI to Provide Sales Team for Launch of Noninvasive Prenatal Screening Tests
News Mar 04, 2009
PDI, Inc. and Sequenom Center for Molecular Medicine, LLC (SCMM) announced that PDI has been selected to provide the sales infrastructure to launch and commercialize SCMM's noninvasive prenatal genetic screening tests based on its SEQureDx™ technology.
Under the direction of SCMM management, PDI will support the commercialization of SCMM's fetal Rhesus D genotyping test from a maternal blood sample. This test will reduce the risk to the mother and fetus by providing clinicians early information.
Under the agreement, PDI will also provide sales support to SCMM upon commercialization of its noninvasive Down syndrome (Trisomy 21) test which is expected to be launched in June of this year, as well as other laboratory developed tests.
Under terms of the agreement, PDI in conjunction with the SCMM management team will hire, train and develop a sales team for the Sequenom Center for Molecular Medicine.
An initial wave of business development managers are targeted for the first quarter of 2009, with additional expansion scheduled throughout the second to fourth quarters of 2009. Sales call points will be focused on our obstetrician and perinatal specialist partners. Financial terms of the engagement were not disclosed.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.